Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 14/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6649836 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL7490912 | 0.95 | ITGB3 (0.91) | ITGB3ITGAVITGA2B | |
| Hydrochloric Acid SCHEMBL7033902 | 0.88 | ITGB3 (0.78) | ITGB3ITGAVITGA2B | |
| Hydrochloric Acid SCHEMBL7033899 | 0.88 | ITGB3 (0.78) | ITGB3ITGAVITGA2B | |
| SCHEMBL14387907 | 0.87 | ITGB3 (0.86) | ITGB3ITGAVITGA2B | |
| SCHEMBL23718779 | 0.86 | ITGB3 (0.85) | ITGB3ITGAVITGA2B | |
| SCHEMBL13170290 | 0.86 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL14356381 | 0.86 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL14387730 | 0.86 | ITGB3 (0.85) | ITGB3ITGAVITGA2B | |
| SCHEMBL7036728 | 0.86 | ITGB3 (0.75) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004070009-A2 | TARGETED MULTIVALENT MACROMOLECULES | TARGESOME INC. (US) | 2004-08-19 | — | — | WO | claimed |
| EP-1401818-A2 | TARGETED MULTIVALENT MACROMOLECULES | Targesome, Inc. (US) | 2004-03-31 | — | — | EP | claimed |
| US-20030133972-A1 | Targeted multivalent macromolecules | TARGESOME, INC. | 2003-07-17 | — | — | US | claimed |
| US-20030129223-A1 | Therapeutic agents, comprising a linking carrier, a therapeutic entity associated with the linking carrier, and atleast one targeting entity | TARGESOME, INC. | 2003-07-10 | — | — | US | claimed |
| WO-2002096367-A2 | TARGETED MULTIVALENT MACROMOLECULES | TARGESOME, INC. (US) | 2002-12-05 | — | — | WO | claimed |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | GENESTE HERVE (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| EP-1239877-B1 | COMPOSITION COMPRISING A TNF-ALPHA INHIBITOR AND AN INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONIST | ABBOTT GMBH & CO KG (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | GENESTE HERVE | 2006-07-20 | — | — | US | disclosed |
| WO-2004070009-A2 | TARGETED MULTIVALENT MACROMOLECULES | TARGESOME INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| EP-1420831-A1 | LIPID CONSTRUCTS AS THERAPEUTIC AND IMAGING AGENTS | Targesome, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| EP-1401818-A2 | TARGETED MULTIVALENT MACROMOLECULES | Targesome, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030133972-A1 | Targeted multivalent macromolecules | TARGESOME, INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030129223-A1 | Therapeutic agents, comprising a linking carrier, a therapeutic entity associated with the linking carrier, and atleast one targeting entity | TARGESOME, INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003011345-A1 | LIPID CONSTRUCTS AS THERAPEUTIC AND IMAGING AGENTS | TARGESOME, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2002096367-A2 | TARGETED MULTIVALENT MACROMOLECULES | TARGESOME, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030133972-A1 | Targeted multivalent macromolecules | CLTB, ILK, CD44 | ITGB3 290/4885ITGAV 72/4885ITGA2B 138/4885 |
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | ITGB3, IL6ST, IL1RN | ITGB3 1/4885ITGAV 11/4885ITGA2B 10/4885 |
| US-20030129223-A1 | Therapeutic agents, comprising a linking carrier, a therapeutic entity associated with the linking carrier, and atleast one targeting entity | CD47, TSG101, ILK | ITGB3 831/4885ITGAV 207/4885ITGA2B 308/4885 |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | ITGB3 3/4885ITGAV 4/4885ITGA2B 12/4885 |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGAV 2/4885ITGA2B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.